Orchid Pharma antibiotic API plant passes US FDA inspection

By Gareth Macdonald

- Last updated on GMT

Related tags Pharmaceutical drug

Orchid Pharma antibiotic API plant passes US FDA inspection
API firm Orchid Pharma has passed a US Food and Drug Administration (FDA) inspection at its facility in Tamil Nadu, India.

The facility in Alathur was visited by the US regulator last August according to Orchid, which announced it received an FDA Establishment Inspection Report (EIR) in a filing​ on the Bombay Stock Exchange (BSE) today. 

Orchid makes antibiotic active pharmaceutical ingredients (APIs) – primarily cephalosporin - at the site.

Operations at the facility were suspending in December​ as a result of flooding, which had a negative impact on the firm according to managing director K Raghavendra Rao.

Despite the business interruption sustained on account of unprecedented torrential rains in December 2015, the company is confident of regaining the traction on account of growth measures being initiated including launch of new products and long term financial arrangements​.”

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Products

View more

Webinars